DBP

:   diastolic blood pressure

ECG

:   electrocardiogram

EoT

:   end of treatment

FAS

:   full analysis set

HRQoL

:   health‐related quality of life

IMI

:   imidafenacin

MIRA

:   mirabegron

MVV

:   mean volume voided

OAB

:   overactive bladder

OAB‐q SF

:   overactive bladder questionnaire short form

OABSS

:   overactive bladder symptom score

PRO

:   propiverine

PVR

:   post‐void residual

QTcF

:   QT interval corrected for heart rate by Fridericia\'s formula

SAF

:   safety analysis set

SBP

:   systolic blood pressure

SD

:   standard deviation

SOLI

:   solifenacin

TEAE

:   treatment‐emergent adverse event

TOL

:   tolterodine

Introduction {#iju13868-sec-0005}
============

OAB is characterized by urinary urgency, with or without urgency urinary incontinence, usually with increased daytime frequency and nocturia.[1](#iju13868-bib-0001){ref-type="ref"} The syndrome is known to have a substantial impact on HRQoL and rates of depression.[2](#iju13868-bib-0002){ref-type="ref"}

Although antimuscarinics are the cornerstone of pharmacotherapy for OAB symptoms, they are associated with specific anticholinergic side‐effects, including dry mouth and constipation.[3](#iju13868-bib-0003){ref-type="ref"} Therefore, therapeutics that do not show these drawbacks could improve patient well being.

The β3‐adrenoreceptor agonist, MIRA, has a distinct mechanism of action from antimuscarinics[4](#iju13868-bib-0004){ref-type="ref"}, [5](#iju13868-bib-0005){ref-type="ref"} and is therefore a potential alternative treatment for OAB symptoms. The efficacy and safety of MIRA has been proved in several phase III clinical trials.[6](#iju13868-bib-0006){ref-type="ref"}, [7](#iju13868-bib-0007){ref-type="ref"} Additional studies have shown that MIRA appears to be as effective as antimuscarinics and shows a lower incidence of drug‐related TEAEs.[8](#iju13868-bib-0008){ref-type="ref"}, [9](#iju13868-bib-0009){ref-type="ref"} One‐year persistence rates of up to 66.0% have been reported, with improved persistence and adherence versus antimuscarinic therapy.[10](#iju13868-bib-0010){ref-type="ref"}, [11](#iju13868-bib-0011){ref-type="ref"}

International urological associations recommend MIRA and antimuscarinics for treating patients with OAB symptoms.[12](#iju13868-bib-0012){ref-type="ref"}, [13](#iju13868-bib-0013){ref-type="ref"} However, even when favorable results are achieved in clinical studies, poor responses might be noted in the real‐world setting.[14](#iju13868-bib-0014){ref-type="ref"} Poor responders to initial treatment might achieve an improved outcome if they subsequently receive MIRA and an antimuscarinic in combination.

The favorable efficacy and safety profile of MIRA add‐on therapy was shown in patients with OAB symptoms who did not respond to initial SOLI treatment in the MILAI and BESIDE studies.[15](#iju13868-bib-0015){ref-type="ref"}, [16](#iju13868-bib-0016){ref-type="ref"} Alternatively, if MIRA is used as first‐line treatment, antimuscarinic add‐on therapy could be considered in patients experiencing a suboptimal response to MIRA.

Previous combination studies either involved add‐on treatment with MIRA[15](#iju13868-bib-0015){ref-type="ref"}, [16](#iju13868-bib-0016){ref-type="ref"} or concurrent use of both therapeutics[17](#iju13868-bib-0017){ref-type="ref"}, [18](#iju13868-bib-0018){ref-type="ref"} over a 12--16 week treatment period.[15](#iju13868-bib-0015){ref-type="ref"}, [16](#iju13868-bib-0016){ref-type="ref"}, [17](#iju13868-bib-0017){ref-type="ref"}, [18](#iju13868-bib-0018){ref-type="ref"} However, MIRA and antimuscarinics in combination might be used for long periods in clinical practice. Prolonged combination therapy might be associated with specific cumulative or delayed events and might have an additive effect on certain TEAEs. Therefore, the objectives of this MILAI II study were to evaluate the long‐term safety (primary objective) and efficacy (secondary objective) of antimuscarinic add‐on therapy to MIRA over 52 weeks in patients with OAB symptoms in Japan. The antimuscarinics investigated were the four main therapeutics used in Japan when the study was planned (SOLI, PRO, IMI, and TOL).

Methods {#iju13868-sec-0006}
=======

Study design {#iju13868-sec-0007}
------------

This was a multicenter, randomized, open‐label, phase IV study in patients with OAB symptoms treated with MIRA (ClinicalTrials.gov: NCT02294396) that was carried out from October 2014 to September 2016 at 60 sites in Japan (Fig. [1](#iju13868-fig-0001){ref-type="fig"}).

![Study design. †Once daily. †Eligibility criteria were verified. §Informed consent was obtained. ¶Furthermore, the patient was considered by the investigator to have no safety concerns and agreed to the increased dose (in the event of a TEAE, the dose could be reduced to the initial dosage). ††If the PRO dose was doubled, patients received a 20‐mg dose twice daily. ††Twice daily (total daily dose shown).](IJU-26-342-g001){#iju13868-fig-0001}

The study was carried out in accordance with the Declaration of Helsinki and International Council for Harmonisation guidelines. The protocol was approved by the institutional review board for each site and all patients provided written informed consent.

Study duration was 54 weeks; a 2‐week screening period and a 52‐week treatment period. Eligible patients were aged ≥20 years, had received previous treatment with MIRA 50 mg for ≥6 weeks, and had residual OAB symptoms (OABSS total score ≥3 points, OABSS question 3 score ≥2 points). Full inclusion and exclusion criteria are in Table [S1](#iju13868-sup-0004){ref-type="supplementary-material"}.

During screening, eligible patients received oral MIRA 50 mg once daily after breakfast. Using MIRA as a first choice therapeutic was based on daily clinical practice in Japan. Patients meeting the final eligibility criteria were subsequently randomized to receive a combination of MIRA 50 mg/day with SOLI 5 mg/day, PRO 20 mg/day, IMI 0.2 mg/day, or extended‐release TOL 4 mg/day for 52 weeks (1:1:1:1 ratio). All treatments were taken orally once daily after breakfast, except for IMI which was also taken after dinner. At week 8, the dose of SOLI, PRO, or IMI could be doubled (if a patient had a poor response to the study drugs, was considered by the investigator to have no safety concerns, and agreed to the dose increase \[TOL dose could not be increased because of prescribing restrictions\]). If a TEAE developed after the dose increase, the dose could be reduced to the original level at the investigator\'s discretion. Subsequent dose re‐escalations were not permitted.

Study assessments {#iju13868-sec-0008}
-----------------

Safety (primary objective) was assessed throughout the study using TEAEs; vital signs, measured by patients on awakening and 6 h post‐dose; 12‐lead ECGs, including QTcF measurements; PVR volume; and laboratory evaluations.

Efficacy assessments (secondary objective) included change from baseline in OABSS total score; OAB‐q SF score; micturitions, urgency episodes, urinary incontinence episodes, and urgency urinary incontinence episodes/24 h; MVV per micturition; and number of night‐time micturitions. Patients completed a paper micturition diary for the 3 days before each site visit. The diary included data on the number of micturitions, urgency episodes and urgency urinary incontinence episodes, and volume voided per micturition. Efficacy assessments were carried out at baseline; weeks 4, 8, 12, 16, 28, 40, and 52; and at EoT, except for the OABSS (no week 40) and the OAB‐q SF (only baseline; weeks 12, 28, and 52; and EoT).

Statistical analysis {#iju13868-sec-0009}
--------------------

The target number of patients was determined to be 150 in each group (600 patients altogether). This took into account the estimated number of patients discontinuing from the study during treatment.[19](#iju13868-bib-0019){ref-type="ref"} Randomization was carried out by the registration center (Bell Medical Solutions, Inc., Tokyo, Japan). Before treatment initiation, the site staff contacted the registration center to determine the treatment allocation.

Safety and demographic data were evaluated using the SAF (patients who received at least one dose of study drug). Efficacy data were evaluated using the FAS (patients who received at least one dose of study drug and provided data for at least one variable before and after treatment initiation).

Categorical data were summarized by the number and percentage of patients; descriptive statistics were used to analyze continuous variables. For efficacy variables, changes from baseline were evaluated using a one‐sample *t*‐test. Owing to the different nature of the antimuscarinics, it was judged that direct statistical comparison of the effectiveness of the combination regimens was not appropriate.

Results {#iju13868-sec-0010}
=======

Study population {#iju13868-sec-0011}
----------------

Overall, 730 patients entered screening, of whom 649 were randomized and 647 were included in both the SAF and the FAS (Fig. [2](#iju13868-fig-0002){ref-type="fig"}). Most patients were women (570 \[88.1%\] patients), with a mean age of 65 years, and a mean OAB duration of 77.2 months (Table [1](#iju13868-tbl-0001){ref-type="table"}). All treatment groups were generally similar regarding patient demographics and baseline characteristics.

![Patient disposition. †Patients who signed informed consent but discontinued before study treatment were defined as screen failures. †Patients who completed screening but discontinued before randomization were defined as run‐in failures. §Patients who received at least one dose of study drug. ¶Patients who received at least one dose of study drug and provided data for at least one variable before and after treatment initiation.](IJU-26-342-g002){#iju13868-fig-0002}

###### 

Patient demographics and baseline characteristics

  Variable                                                        MIRA + SOLI (*n* = 166)   MIRA + PRO (*n* = 161)   MIRA + IMI (*n* = 161)   MIRA + TOL (*n* = 159)   Total (*n* = 647)
  --------------------------------------------------------------- ------------------------- ------------------------ ------------------------ ------------------------ ---------------------
  Sex, *n* (%)                                                                                                                                                         
  Male                                                            20 (12.0)                 17 (10.6)                15 (9.3)                 25 (15.7)                77 (11.9)
  Female                                                          146 (88.0)                144 (89.4)               146 (90.7)               134 (84.3)               570 (88.1)
  Age in years                                                                                                                                                         
  Mean (SD, range)                                                64.6 (9.4, 45--89)        64.0 (9.3, 42--82)       65.7 (8.7, 47--85)       65.7 (10.0, 40--85)      65.0 (9.4, 40--89)
  Age group, *n* (%)                                                                                                                                                   
  \<65 years                                                      86 (51.8)                 82 (50.9)                65 (40.4)                65 (40.9)                298 (46.1)
  ≥65 years                                                       80 (48.2)                 79 (49.1)                96 (59.6)                94 (59.1)                349 (53.9)
  Duration of OAB in months                                                                                                                                            
  Mean (SD) \[*n*\]                                               69.3 (68.2) \[162\]       78.8 (88.9) \[158\]      83.3 (94.2) \[156\]      77.9 (85.8) \[155\]      77.2 (84.7) \[631\]
  Median (range)                                                  49.0 (1--334)             53.0 (1--602)            59.0 (1--545)            55.0 (1--565)            55.0 (1--602)
  Status of urinary incontinence, *n* (%)                                                                                                                              
  Absent                                                          35 (21.1)                 25 (15.5)                16 (9.9)                 22 (13.8)                98 (15.1)
  Urgency urinary incontinence                                    99 (59.6)                 100 (62.1)               96 (59.6)                91 (57.2)                386 (59.7)
  Mixed urinary incontinence                                      32 (19.3)                 36 (22.4)                49 (30.4)                46 (28.9)                163 (25.2)
  OAB severity (mean no. micturitions at baseline), *n* (%)                                                                                                            
  \<10                                                            85 (51.2)                 76 (47.2)                85 (52.8)                79 (49.7)                325 (50.2)
  ≥10 to \<15                                                     74 (44.6)                 74 (46.0)                64 (39.8)                69 (43.4)                281 (43.4)
  ≥15                                                             7 (4.2)                   11 (6.8)                 12 (7.5)                 11 (6.9)                 41 (6.3)
  Urinary incontinence episodes at baseline, *n* (%)                                                                                                                   
  No                                                              75 (45.2)                 66 (41.0)                58 (36.0)                63 (39.6)                262 (40.5)
  Yes                                                             91 (54.8)                 95 (59.0)                103 (64.0)               96 (60.4)                385 (59.5)
  OABSS total score, mean (SD)                                    7.4 (2.6)                 7.7 (2.5)                7.8 (2.3)                7.7 (2.3)                7.6 (2.4)
  OAB‐q SF symptom severity score, mean (SD)                      32.81 (20.78)             32.36 (21.23)            32.92 (19.45)            34.23 (22.60)            33.08 (21.00)
  OAB‐q SF total HRQoL score, mean (SD)                           75.16 (17.65)             77.36 (16.11)            74.85 (18.50)            75.37 (19.33)            75.68 (17.91)
  Micturitions/24 h, mean (SD)                                    10.06 (2.59)              10.37 (2.65)             10.13 (2.92)             10.20 (2.62)             10.19 (2.69)
  Urgency episodes/24 h, mean (SD) \[*n*\]                        3.26 (2.46) \[153\]       3.12 (2.67) \[148\]      3.27 (2.20) \[150\]      3.15 (2.54) \[148\]      3.20 (2.47) \[599\]
  Urinary incontinence episodes/24 h, mean (SD) \[*n*\]           1.62 (1.62) \[91\]        1.59 (1.83) \[95\]       1.47 (1.35) \[103\]      1.55 (1.76) \[96\]       1.56 (1.64) \[385\]
  Urgency urinary incontinence episodes/24 h, mean (SD) \[*n*\]   1.55 (1.47) \[80\]        1.39 (1.45) \[82\]       1.30 (1.16) \[86\]       1.31 (1.62) \[85\]       1.38 (1.43) \[333\]
  MVV in mL/micturition, mean (SD)                                166.600 (50.404)          170.064 (63.781)         169.309 (50.324)         167.542 (54.320)         168.368 (54.839)
  Night‐time micturitions, mean (SD) \[*n*\]                      1.50 (0.96) \[142\]       1.68 (1.08) \[133\]      1.61 (1.29) \[141\]      1.67 (1.04) \[132\]      1.61 (1.10) \[548\]

Data shown for the FAS (patients who received at least one dose of study drug and provided data for at least one variable before and after treatment initiation).

John Wiley & Sons, Ltd

At week 8, most patients (595 \[92.0%\] patients) did not have their antimuscarinic dose increased. Dose increases were administered to 15 (9.0%) MIRA and SOLI patients, 15 (9.3%) MIRA and PRO patients, and 22 (13.7%) MIRA and IMI patients. Seven (4.2%), four (2.5%), and five (3.1%) patients from the SOLI, PRO, and IMI groups, respectively, had their dose decreased back to the initial dosage.

Safety {#iju13868-sec-0012}
------

Overall, 519 (80.2%) patients experienced at least one TEAE (Table [2](#iju13868-tbl-0002){ref-type="table"}). Furthermore, 303 (46.8%) patients experienced at least one drug‐related TEAE with similar incidences for all groups. Drug‐related TEAEs leading to treatment withdrawal occurred in 47 (7.3%) patients; all occurrences were mild or moderate in severity.

###### 

TEAEs occurring during the course of the study

                                            TEAE, *n* (%)   Drug‐related TEAE, *n* (%)                                                                                          
  ----------------------------------------- --------------- ---------------------------- ------------ ------------ ------------ ----------- ----------- ----------- ----------- ------------
  TEAE                                      131 (78.9)      135 (83.9)                   133 (82.6)   120 (75.5)   519 (80.2)   76 (45.8)   81 (50.3)   72 (44.7)   74 (46.5)   303 (46.8)
  Serious TEAE                              10 (6.0)        4 (2.5)                      5 (3.1)      9 (5.7)      28 (4.3)     0           1 (0.6)     0           1 (0.6)     2 (0.3)
  TEAE leading to withdrawal of treatment   23 (13.9)       19 (11.8)                    16 (9.9)     18 (11.3)    76 (11.7)    12 (7.2)    17 (10.6)   10 (6.2)    8 (5.0)     47 (7.3)
  TEAE leading to death                     0               0                            0            1 (0.6)      1 (0.2)      0           0           0           0           0
  TEAEs (≥3.0% for any group)                                                                                                                                                   
  Dry mouth                                 32 (19.3)       51 (31.7)                    40 (24.8)    40 (25.2)    163 (25.2)   31 (18.7)   51 (31.7)   40 (24.8)   40 (25.2)   162 (25.0)
  Nasopharyngitis                           35 (21.1)       39 (24.2)                    34 (21.1)    32 (20.1)    140 (21.6)   0           0           0           0           0
  Constipation                              37 (22.3)       27 (16.8)                    24 (14.9)    19 (11.9)    107 (16.5)   33 (19.9)   26 (16.1)   23 (14.3)   18 (11.3)   100 (15.5)
  Cystitis                                  18 (10.8)       13 (8.1)                     25 (15.5)    10 (6.3)     66 (10.2)    0           0           4 (2.5)     0           4 (0.6)
  Dysuria                                   8 (4.8)         4 (2.5)                      3 (1.9)      7 (4.4)      22 (3.4)     8 (4.8)     4 (2.5)     3 (1.9)     7 (4.4)     22 (3.4)
  Back pain                                 3 (1.8)         5 (3.1)                      6 (3.7)      4 (2.5)      18 (2.8)     0           0           0           0           0
  Contusion                                 4 (2.4)         6 (3.7)                      3 (1.9)      5 (3.1)      18 (2.8)     0           0           0           0           0
  Abdominal discomfort                      7 (4.2)         4 (2.5)                      4 (2.5)      2 (1.3)      17 (2.6)     5 (3.0)     2 (1.2)     3 (1.9)     2 (1.3)     12 (1.9)
  Eczema                                    5 (3.0)         2 (1.2)                      6 (3.7)      4 (2.5)      17 (2.6)     1 (0.6)     0           1 (0.6)     0           2 (0.3)
  Gastroesophageal reflux disease           2 (1.2)         6 (3.7)                      4 (2.5)      5 (3.1)      17 (2.6)     0           3 (1.9)     2 (1.2)     3 (1.9)     8 (1.2)
  Residual urine volume increased           6 (3.6)         8 (5.0)                      1 (0.6)      2 (1.3)      17 (2.6)     6 (3.6)     7 (4.3)     1 (0.6)     2 (1.3)     16 (2.5)
  Pharyngitis                               6 (3.6)         4 (2.5)                      4 (2.5)      2 (1.3)      16 (2.5)     0           0           0           0           0
  Dermatitis contact                        3 (1.8)         7 (4.3)                      2 (1.2)      2 (1.3)      14 (2.2)     0           0           0           0           0
  Gastroenteritis                           3 (1.8)         2 (1.2)                      5 (3.1)      2 (1.3)      12 (1.9)     0           0           0           0           0
  Osteoarthritis                            5 (3.0)         2 (1.2)                      3 (1.9)      2 (1.3)      12 (1.9)     0           0           0           0           0
  Gastritis                                 2 (1.2)         5 (3.1)                      4 (2.5)      0            11 (1.7)     0           1 (0.6)     2 (1.2)     0           3 (0.5)
  Headache                                  5 (3.0)         4 (2.5)                      0            2 (1.3)      11 (1.7)     2 (1.2)     2 (1.2)     0           1 (0.6)     5 (0.8)
  Vomiting                                  1 (0.6)         2 (1.2)                      5 (3.1)      3 (1.9)      11 (1.7)     0           0           1 (0.6)     0           1 (0.2)
  Dizziness                                 2 (1.2)         5 (3.1)                      0            3 (1.9)      10 (1.5)     1 (0.6)     1 (0.6)     0           1 (0.6)     3 (0.5)
  Dental caries                             0               6 (3.7)                      3 (1.9)      0            9 (1.4)      0           0           0           0           0
  ECG QT prolonged                          1 (0.6)         2 (1.2)                      5 (3.1)      1 (0.6)      9 (1.4)      1 (0.6)     2 (1.2)     4 (2.5)     1 (0.6)     8 (1.2)
  Osteoporosis                              1 (0.6)         5 (3.1)                      2 (1.2)      1 (0.6)      9 (1.4)      0           0           0           0           0
  Cataract                                  1 (0.6)         1 (0.6)                      1 (0.6)      5 (3.1)      8 (1.2)      0           0           0           0           0
  Dyspepsia                                 0               5 (3.1)                      1 (0.6)      1 (0.6)      7 (1.1)      0           2 (1.2)     1 (0.6)     1 (0.6)     4 (0.6)

Data shown for the SAF (patients who received at least one dose of study drug).

John Wiley & Sons, Ltd

In total, 28 (4.3%) patients reported at least one serious TEAE. Two serious TEAEs were considered by the investigator to be possibly drug‐related. One patient treated with MIRA and PRO experienced a serious TEAE of atrial fibrillation, which resolved 10 days after treatment withdrawal. One patient treated with MIRA and TOL reported a serious TEAE of colitis ischemic, which resolved 23 days after treatment interruption and did not recur after restarting treatment. Another patient treated with MIRA and TOL died after a serious TEAE of acute respiratory distress syndrome. This event was considered to be unrelated to study treatment, as it occurred during drug withdrawal.

The most commonly reported TEAEs were dry mouth (163 \[25.2%\] patients), nasopharyngitis (140 \[21.6%\] patients), and constipation (107 \[16.5%\] patients). Compared with the other regimens, slightly higher incidences of dry mouth and constipation were observed in the MIRA and PRO and MIRA and SOLI groups, respectively. For drug‐related TEAEs, the most commonly reported events were dry mouth (162 \[25.0%\] patients) and constipation (100 \[15.5%\] patients). Time‐dependent changes were apparent in the prevalence of some TEAEs, with an overall higher prevalence in the earlier part of the study. In particular, dry mouth, constipation, dysuria, and residual urine volume increased were more commonly reported in the earlier stages of the study. There was no trend in the time onset of the other TEAEs (Table [3](#iju13868-tbl-0003){ref-type="table"}).

###### 

First onset of TEAEs (≥3.0% for any group) by time interval

                                    Time interval (days)                                                                                              
  --------------------------------- ---------------------- ---------- ---------- ------------ ---------- ---------- ----------- ---------- ---------- ---------
  Overall TEAEs, *n* (%)            96 (14.8)              38 (5.9)   51 (7.9)   107 (17.0)   57 (9.5)   33 (5.7)   63 (11.2)   46 (8.6)   25 (4.8)   3 (2.3)
  Dry mouth                         70 (10.8)              14 (2.2)   9 (1.4)    30 (4.8)     17 (2.8)   9 (1.6)    7 (1.2)     6 (1.1)    1 (0.2)    0
  Nasopharyngitis                   1 (0.2)                4 (0.6)    11 (1.7)   17 (2.7)     14 (2.3)   6 (1.0)    24 (4.3)    37 (6.9)   26 (5.0)   0
  Constipation                      13 (2.0)               13 (2.0)   17 (2.6)   20 (3.2)     17 (2.8)   8 (1.4)    13 (2.3)    4 (0.7)    2 (0.4)    0
  Cystitis                          1 (0.2)                0          3 (0.5)    4 (0.6)      10 (1.7)   5 (0.9)    17 (3.0)    17 (3.2)   8 (1.5)    1 (0.8)
  Dysuria                           6 (0.9)                2 (0.3)    2 (0.3)    4 (0.6)      4 (0.7)    1 (0.2)    2 (0.4)     1 (0.2)    0          0
  Back pain                         0                      0          0          1 (0.2)      2 (0.3)    1 (0.2)    6 (1.1)     5 (0.9)    3 (0.6)    0
  Contusion                         0                      0          2 (0.3)    3 (0.5)      2 (0.3)    0          3 (0.5)     5 (0.9)    3 (0.6)    0
  Abdominal discomfort              1 (0.2)                3 (0.5)    0          1 (0.2)      3 (0.5)    1 (0.2)    4 (0.7)     2 (0.4)    2 (0.4)    0
  Eczema                            2 (0.3)                0          0          4 (0.6)      1 (0.2)    1 (0.2)    4 (0.7)     3 (0.6)    2 (0.4)    0
  Gastroesophageal reflux disease   2 (0.3)                1 (0.2)    0          0            2 (0.3)    1 (0.2)    2 (0.4)     7 (1.3)    2 (0.4)    0
  Residual urine volume increased   1 (0.2)                0          3 (0.5)    10 (1.6)     2 (0.3)    0          1 (0.2)     0          0          0
  Pharyngitis                       1 (0.2)                0          2 (0.3)    0            2 (0.3)    1 (0.2)    3 (0.5)     4 (0.7)    3 (0.6)    0
  Dermatitis contact                0                      0          0          2 (0.3)      1 (0.2)    1 (0.2)    5 (0.9)     5 (0.9)    0          0
  Gastroenteritis                   1 (0.2)                1 (0.2)    1 (0.2)    0            0          0          4 (0.7)     3 (0.6)    2 (0.4)    0
  Osteoarthritis                    0                      0          1 (0.2)    1 (0.2)      0          0          5 (0.9)     2 (0.4)    3 (0.6)    0
  Gastritis                         0                      0          0          2 (0.3)      0          1 (0.2)    3 (0.5)     3 (0.6)    2 (0.4)    0
  Headache                          3 (0.5)                0          1 (0.2)    1 (0.2)      2 (0.3)    2 (0.3)    1 (0.2)     0          1 (0.2)    0
  Vomiting                          0                      1 (0.2)    1 (0.2)    0            2 (0.3)    4 (0.7)    3 (0.5)     0          0          0
  Dizziness                         1 (0.2)                0          0          1 (0.2)      1 (0.2)    1 (0.2)    3 (0.5)     2 (0.4)    1 (0.2)    0
  Dental caries                     0                      0          0          2 (0.3)      2 (0.3)    0          1 (0.2)     2 (0.4)    2 (0.4)    0
  ECG QT prolonged                  0                      0          0          4 (0.6)      1 (0.2)    1 (0.2)    3 (0.5)     0          0          0
  Osteoporosis                      0                      0          1 (0.2)    0            1 (0.2)    1 (0.2)    2 (0.4)     2 (0.4)    2 (0.4)    0
  Cataract                          0                      0          0          1 (0.2)      0          0          5 (0.9)     1 (0.2)    1 (0.2)    0
  Dyspepsia                         1 (0.2)                2 (0.3)    0          1 (0.2)      0          0          1 (0.2)     2 (0.4)    0          0

Data shown for the SAF (patients who received at least one dose of study drug).

John Wiley & Sons, Ltd

For pulse rate, no marked change from baseline to EoT was observed for any combination (Table [4](#iju13868-tbl-0004){ref-type="table"}). Over the treatment period, pulse rate remained constant in the MIRA and SOLI and MIRA and IMI groups and increased slightly in the MIRA and PRO and MIRA and TOL groups (Fig. [S1](#iju13868-sup-0001){ref-type="supplementary-material"}). No marked change from baseline to EoT was observed in SBP or DBP for any group (Figs [S2](#iju13868-sup-0002){ref-type="supplementary-material"},[S3](#iju13868-sup-0003){ref-type="supplementary-material"}).

###### 

Vital sign ECG, and PVR volume results

  Variable                                                MIRA + SOLI (*n* = 166)   MIRA + PRO (*n* = 161)   MIRA + IMI (*n* = 161)   MIRA + TOL (*n* = 159)
  ------------------------------------------------------- ------------------------- ------------------------ ------------------------ ------------------------
  Vital signs                                                                                                                         
  Pulse rate in b.p.m. on awakening, mean (SD) \[*n*\]                                                                                
  Baseline                                                70.07 (8.15) \[166\]      69.15 (8.19) \[161\]     69.17 (7.25) \[160\]     68.51 (8.15) \[159\]
  EoT                                                     70.68 (7.55) \[159\]      72.35 (9.68) \[155\]     69.26 (6.76) \[157\]     70.64 (8.39) \[156\]
  Change from baseline to EoT                             0.68 (4.95) \[159\]       3.19 (6.54) \[155\]      0.09 (5.74) \[156\]      2.11 (5.20) \[156\]
  Pulse rate in b.p.m. 6 h post‐dose, mean (SD) \[*n*\]                                                                               
  Baseline                                                74.91 (8.80) \[166\]      73.87 (9.16) \[160\]     74.56 (8.08) \[161\]     74.09 (8.68) \[159\]
  EoT                                                     74.93 (7.99) \[159\]      76.74 (10.09) \[155\]    73.22 (7.94) \[157\]     77.55 (9.25) \[156\]
  Change from baseline to EoT                             0.17 (6.25) \[159\]       2.86 (6.62) \[154\]      −1.27 (6.67) \[157\]     3.40 (6.86) \[156\]
  SBP in mmHg on awakening, mean (SD) \[*n*\]                                                                                         
  Baseline                                                128.91 (16.03) \[166\]    129.75 (17.22) \[161\]   127.21 (16.34) \[160\]   129.22 (16.41) \[159\]
  EoT                                                     126.91 (15.02) \[159\]    126.86 (15.87) \[155\]   126.28 (15.24) \[157\]   126.65 (14.62) \[156\]
  Change from baseline to EoT                             −1.60 (11.56) \[159\]     −2.88 (9.08) \[155\]     −0.86 (9.64) \[156\]     −2.31 (10.14) \[156\]
  SBP in mmHg 6 h post‐dose, mean (SD) \[*n*\]                                                                                        
  Baseline                                                125.45 (13.52) \[166\]    125.44 (13.99) \[160\]   125.20 (14.35) \[161\]   127.15 (13.74) \[159\]
  EoT                                                     125.06 (13.24) \[159\]    123.78 (13.11) \[155\]   123.45 (14.03) \[157\]   124.66 (13.40) \[156\]
  Change from baseline to EoT                             −0.46 (10.53) \[159\]     −1.55 (9.27) \[154\]     −1.64 (9.23) \[157\]     −2.35 (9.86) \[156\]
  DBP in mmHg on awakening, mean (SD) \[*n*\]                                                                                         
  Baseline                                                80.65 (9.14) \[166\]      80.45 (10.36) \[161\]    79.08 (10.04) \[160\]    79.40 (9.82) \[159\]
  EoT                                                     79.40 (8.83) \[159\]      79.46 (9.96) \[155\]     78.52 (9.45) \[157\]     78.72 (9.52) \[156\]
  Change from baseline to EoT                             −0.90 (6.48) \[159\]      −1.00 (6.07) \[155\]     −0.64 (6.31) \[156\]     −0.54 (6.81) \[156\]
  DBP in mmHg 6 h post‐dose, mean (SD) \[*n*\]                                                                                        
  Baseline                                                78.03 (8.38) \[166\]      77.67 (9.23) \[160\]     77.30 (9.32) \[161\]     77.85 (8.76) \[159\]
  EoT                                                     77.33 (8.40) \[159\]      77.12 (9.24) \[155\]     75.55 (9.13) \[157\]     78.12 (8.89) \[156\]
  Change from baseline to EoT                             −0.54 (6.48) \[159\]      −0.56 (6.25) \[154\]     −1.79 (5.92) \[157\]     0.33 (7.17) \[156\]
  ECGs                                                                                                                                
  QTcF in ms, mean (SD) \[*n*\]                                                                                                       
  Baseline                                                418.5 (17.4) \[164\]      419.2 (16.9) \[161\]     416.4 (17.3) \[160\]     415.4 (15.6) \[158\]
  EoT                                                     420.5 (16.6) \[164\]      418.0 (16.7) \[160\]     416.0 (17.5) \[160\]     418.5 (15.9) \[159\]
  Change from baseline to EoT                             1.8 (11.6) \[162\]        −1.2 (10.8) \[160\]      −0.4 (12.8) \[159\]      3.0 (10.6) \[158\]
  Absolute QTcF at EoT, *n* (%)                                                                                                       
  ≤450 ms                                                 158 (96.3)                157 (98.1)               158 (98.8)               155 (97.5)
  \>450 to ≤480 ms                                        6 (3.7)                   2 (1.3)                  2 (1.3)                  4 (2.5)
  \>480 to ≤500 ms                                        0                         1 (0.6)                  0                        0
  Change in QTcF from baseline to EoT, *n* (%)                                                                                        
  \<0 ms                                                  70 (43.2)                 86 (53.8)                77 (48.4)                54 (34.2)
  \>0 to ≤30 ms                                           91 (56.2)                 73 (45.6)                80 (50.3)                104 (65.8)
  \>30 to ≤60 ms                                          1 (0.6)                   1 (0.6)                  2 (1.3)                  0
  PVR volume                                                                                                                          
  PVR volume in mL, mean (SD) \[*n*\]                                                                                                 
  Baseline                                                11.02 (15.43) \[166\]     10.43 (17.07) \[161\]    9.74 (14.35) \[161\]     9.10 (14.41) \[159\]
  EoT                                                     19.31 (43.18) \[164\]     17.27 (34.86) \[160\]    14.26 (26.04) \[161\]    15.04 (36.68) \[159\]
  Change from baseline to EoT                             8.17 (39.42) \[164\]      6.83 (32.20) \[160\]     4.52 (23.51) \[161\]     5.94 (35.83) \[159\]

Data shown for the SAF (patients who received at least one dose of study drug).

John Wiley & Sons, Ltd

The QTcF interval remained reasonably constant from baseline to EoT and the observed changes ranged from −1.2 to 3.0 ms. No patient had a change in QTcF interval \>60 ms from baseline to EoT. One MIRA and PRO patient had a QTcF interval \>480 ms at week 16 (489 ms) and was discontinued from the study.

No notable change from baseline was found for PVR volume in any group. Drug‐related residual urine volume increased was reported by 16 (2.5%) patients. No drug‐related urinary retention was noted during the study. No clinically significant changes from baseline were found for any laboratory parameter.

Efficacy {#iju13868-sec-0013}
--------

OABSS significantly improved by ≥3 points from baseline to EoT in all treatment groups (Table [5](#iju13868-tbl-0005){ref-type="table"}). From baseline to EoT, significant improvements of ≥10 points in both of the OAB‐q SF measures (symptom severity score and total HRQoL score) were observed in all treatment groups. Significant improvements in OABSS and OAB‐q SF were observed at the first time point evaluated (week 4 for OABSS, week 12 for OAB‐q SF) and were maintained throughout the entire 52‐week treatment period (Fig. [3](#iju13868-fig-0003){ref-type="fig"}).

###### 

Change from baseline to EoT in efficacy parameters

  Variable                                                        MIRA + SOLI (*n* = 166)                                           MIRA + PRO (*n* = 161)                                            MIRA + IMI (*n* = 161)                                            MIRA + TOL (*n* = 159)
  --------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------- -----------------------------------------------------------------
  OABSS total score, mean (SD) \[*n*\]                            −3.9 (2.7)[\*](#iju13868-note-0005){ref-type="fn"} \[164\]        −4.1 (2.6)[\*](#iju13868-note-0005){ref-type="fn"} \[160\]        −3.9 (2.6)[\*](#iju13868-note-0005){ref-type="fn"} \[161\]        −4.2 (2.8)[\*](#iju13868-note-0005){ref-type="fn"} \[159\]
  OAB‐q SF symptom severity score, mean (SD) \[*n*\]              −18.92 (18.42)[\*](#iju13868-note-0005){ref-type="fn"} \[160\]    −18.99 (19.14)[\*](#iju13868-note-0005){ref-type="fn"} \[159\]    −18.89 (18.11)[\*](#iju13868-note-0005){ref-type="fn"} \[159\]    −21.28 (20.99)[\*](#iju13868-note-0005){ref-type="fn"} \[154\]
  OAB‐q SF total HRQoL score, mean (SD) \[*n*\]                   14.38 (14.98)[\*](#iju13868-note-0005){ref-type="fn"} \[160\]     12.46 (13.89)[\*](#iju13868-note-0005){ref-type="fn"} \[159\]     13.99 (16.72)[\*](#iju13868-note-0005){ref-type="fn"} \[159\]     14.36 (17.51)[\*](#iju13868-note-0005){ref-type="fn"} \[154\]
  Micturitions/24 h, mean (SD) \[*n*\]                            −2.18 (1.96)[\*](#iju13868-note-0005){ref-type="fn"} \[159\]      −1.89 (2.08)[\*](#iju13868-note-0005){ref-type="fn"} \[155\]      −1.75 (2.09)[\*](#iju13868-note-0005){ref-type="fn"} \[157\]      −1.91 (2.22)[\*](#iju13868-note-0005){ref-type="fn"} \[156\]
  Urgency episodes/24 h, mean (SD) \[*n*\]                        −2.03 (2.55)[\*](#iju13868-note-0005){ref-type="fn"} \[147\]      −2.24 (2.41)[\*](#iju13868-note-0005){ref-type="fn"} \[143\]      −2.04 (2.19)[\*](#iju13868-note-0005){ref-type="fn"} \[149\]      −2.07 (2.23)[\*](#iju13868-note-0005){ref-type="fn"} \[146\]
  Urinary incontinence episodes/24 h, mean (SD) \[*n*\]           −1.25 (1.48)[\*](#iju13868-note-0005){ref-type="fn"} \[87\]       −1.18 (1.59)[\*](#iju13868-note-0005){ref-type="fn"} \[92\]       −1.03 (1.08)[\*](#iju13868-note-0005){ref-type="fn"} \[101\]      −1.15 (1.52)[\*](#iju13868-note-0005){ref-type="fn"} \[93\]
  Urgency urinary incontinence episodes/24 h, mean (SD) \[*n*\]   −1.20 (1.32)[\*](#iju13868-note-0005){ref-type="fn"} \[76\]       −1.12 (1.33)[\*](#iju13868-note-0005){ref-type="fn"} \[80\]       −0.91 (0.93)[\*](#iju13868-note-0005){ref-type="fn"} \[85\]       −1.05 (1.59)[\*](#iju13868-note-0005){ref-type="fn"} \[82\]
  MVV in mL/micturition, mean (SD) \[*n*\]                        40.004 (45.095)[\*](#iju13868-note-0005){ref-type="fn"} \[159\]   38.691 (46.429)[\*](#iju13868-note-0005){ref-type="fn"} \[155\]   32.854 (44.481)[\*](#iju13868-note-0005){ref-type="fn"} \[157\]   40.683 (46.566)[\*](#iju13868-note-0005){ref-type="fn"} \[156\]
  Night‐time micturitions, mean (SD) \[*n*\]                      −0.47 (0.91)[\*](#iju13868-note-0005){ref-type="fn"} \[137\]      −0.38 (0.88)[\*](#iju13868-note-0005){ref-type="fn"} \[131\]      −0.48 (0.93)[\*](#iju13868-note-0005){ref-type="fn"} \[139\]      −0.48 (0.88)[\*](#iju13868-note-0005){ref-type="fn"} \[130\]

\**P *\<* *0.001 *vs* baseline. Data shown for the FAS (patients who received at least one dose of study drug and provided data for at least one variable before and after treatment initiation).

John Wiley & Sons, Ltd

![Mean change from baseline at each visit in (a) OABSS total score, (b) OAB‐q SF symptom severity score, and (c) OAB‐q SF total HRQoL score. Data shown for the FAS (patients who received at least one dose of study drug and provided data for at least one variable before and after treatment initiation).](IJU-26-342-g003){#iju13868-fig-0003}

For all combination treatments, significant improvements from baseline to EoT were observed in all parameters calculated from the micturition diary entries (micturitions, urgency episodes, urinary incontinence episodes, urgency urinary incontinence episodes, MVV, and night‐time micturitions).

Discussion {#iju13868-sec-0014}
==========

This is the first study to evaluate the long‐term safety and efficacy of add‐on therapy with four different antimuscarinics (SOLI, PRO, IMI, and TOL) in patients with OAB symptoms who were poor responders to initial MIRA treatment. Only one previous study has investigated MIRA in combination with a different antimuscarinic from SOLI; a small 8‐week study of 30 patients with OAB symptoms evaluated the use of PRO add‐on to MIRA therapy.[20](#iju13868-bib-0020){ref-type="ref"}

In the present study, patients received add‐on treatment with antimuscarinics after ≥8 weeks' treatment with MIRA (≥6 weeks before study start and 2 weeks during screening). The rationale for this time frame was based on findings from an efficacy analysis that found that clinical benefits can be achieved after just a few weeks of MIRA treatment.[21](#iju13868-bib-0021){ref-type="ref"}

Add‐on therapy with antimuscarinics was well tolerated over 52 weeks in the present study. Similar incidences of TEAEs, drug‐related TEAEs, serious TEAEs, and the anticholinergic TEAEs of dry mouth and constipation were observed in all treatment groups. Although no monotherapy arms were included, the TEAE results from the present study are supported by findings from previous long‐term Japanese clinical studies investigating the use of antimuscarinics as single agents (except for PRO, where there are a lack of long‐term data).[22](#iju13868-bib-0022){ref-type="ref"}, [23](#iju13868-bib-0023){ref-type="ref"}, [24](#iju13868-bib-0024){ref-type="ref"}, [25](#iju13868-bib-0025){ref-type="ref"} For example, 45.8% of MIRA and SOLI patients reported a drug‐related TEAE in the present study and incidences of 58.8% and 64.6% were reported in a multicenter, open‐label study that involved the administration of SOLI monotherapy (5 or 10 mg) to 252 patients with OAB symptoms.[22](#iju13868-bib-0022){ref-type="ref"} In terms of anticholinergic TEAEs, the incidence of drug‐related constipation was 19.9% for the MIRA and SOLI group in the present study and incidences of 19.0% and 21.2% were reported in the Japanese SOLI monotherapy study.[22](#iju13868-bib-0022){ref-type="ref"} Furthermore, the incidence of dry mouth as a TEAE was 25.2% for the MIRA and TOL group in the present study and an incidence of 33.5% was reported in a 12‐month, open‐label TOL monotherapy study.[23](#iju13868-bib-0023){ref-type="ref"} Importantly, no new safety concerns were observed in the present study after the use of MIRA and antimuscarinics in combination versus previous long‐term studies involving MIRA or antimuscarinics as monotherapies.[11](#iju13868-bib-0011){ref-type="ref"}, [22](#iju13868-bib-0022){ref-type="ref"}, [23](#iju13868-bib-0023){ref-type="ref"}, [24](#iju13868-bib-0024){ref-type="ref"}, [25](#iju13868-bib-0025){ref-type="ref"} Additionally, no cumulative or delayed TEAEs were observed during the present study.

Compared with the present study, lower overall incidences of TEAEs have been reported in most previous SOLI and MIRA combination studies (78.9% *vs* 35.9--59.3%).[15](#iju13868-bib-0015){ref-type="ref"}, [17](#iju13868-bib-0017){ref-type="ref"}, [18](#iju13868-bib-0018){ref-type="ref"} Regarding drug‐related TEAEs, the overall incidence reported here (45.8%) was slightly higher than in earlier combination studies (17.7--44.4%).[15](#iju13868-bib-0015){ref-type="ref"}, [16](#iju13868-bib-0016){ref-type="ref"}, [17](#iju13868-bib-0017){ref-type="ref"}, [18](#iju13868-bib-0018){ref-type="ref"} In agreement with these findings, incidences of dry mouth (19.3%) and constipation (22.3%) after MIRA and SOLI in combination were slightly and noticeably higher, respectively, in the present study than in previous trials evaluating the safety of this combination regimen (dry mouth 5.9--17.3%, constipation 1.3--9.9%).[15](#iju13868-bib-0015){ref-type="ref"}, [17](#iju13868-bib-0017){ref-type="ref"}, [18](#iju13868-bib-0018){ref-type="ref"} The variations in safety findings between the present study and previous SOLI and MIRA combination studies are likely due to differences in study design. The present study involved a longer treatment period than previous trials, had a different order of administration (e.g. MIRA was used as add‐on therapy to SOLI in the BESIDE and MILAI studies[15](#iju13868-bib-0015){ref-type="ref"}, [16](#iju13868-bib-0016){ref-type="ref"}), and involved potential increases in the antimuscarinic dose at week 8 (patients receiving increased doses experienced higher incidences of TEAEs than those receiving lower doses \[data not shown\]).

Previous investigations have indicated that MIRA might marginally increase heart rate,[6](#iju13868-bib-0006){ref-type="ref"}, [7](#iju13868-bib-0007){ref-type="ref"} although the clinical relevance of this is unknown. In the present study, no clinically significant differences in pulse rate from baseline to EoT were observed. For the MIRA and SOLI and MIRA and IMI groups, pulse rate remained constant over the treatment period. Increases in pulse rate of 2.86--3.19 b.p.m. and 2.11--3.40 b.p.m. were observed in the MIRA and PRO and MIRA and TOL groups, respectively. Previous clinical investigations have noted similar increases after the use of PRO (4.4 b.p.m.) or TOL (1.5--2.0 b.p.m.) as single agents.[26](#iju13868-bib-0026){ref-type="ref"}, [27](#iju13868-bib-0027){ref-type="ref"} Administration of the combination regimens did not have a notable effect on SBP or DBP. Supporting this finding, the results of the phase II Symphony study found that negligible changes in blood pressure were observed after the use of SOLI and MIRA in combination.[17](#iju13868-bib-0017){ref-type="ref"}

Unanticipated cardiovascular events were not observed in the present study. This finding is supported by the results of a subanalysis from the BESIDE study, which found no synergistic effect on cardiovascular safety after SOLI and MIRA combination therapy.[28](#iju13868-bib-0028){ref-type="ref"} No clinically significant changes in QTcF intervals from baseline to EoT were observed, regardless of the combination treatment administered, and no patient experienced a QTcF interval \>500 ms or a change in QTcF interval from baseline to EoT of \>60 ms. Similar findings have been reported in both the BESIDE and MILAI studies.[16](#iju13868-bib-0016){ref-type="ref"}, [28](#iju13868-bib-0028){ref-type="ref"}

Statistically significant improvements in efficacy were observed in the present study for all parameters investigated after the administration of all four combination regimens. In this study, clinically significant improvements in OABSS and OAB‐q SF were observed at EoT after the use of combination treatments (changes of ≥3 and ≥10 points denote clinically significant improvements in OABSS and OAB‐q parameters, respectively).[29](#iju13868-bib-0029){ref-type="ref"}, [30](#iju13868-bib-0030){ref-type="ref"} For both OABSS and OAB‐q SF, statistically significant differences from baseline were observed from the first time point evaluated and improvement was maintained throughout the entire treatment period. The significant improvements shown in OABSS and OAB‐q SF in the present study are supported by the SOLI and MIRA combination results from the short‐term MILAI study.[16](#iju13868-bib-0016){ref-type="ref"}

Significant improvements from baseline were observed in all of the efficacy parameters that were assessed using data from the patient micturition diary. Similar findings have been observed in previous SOLI and MIRA combination studies.[15](#iju13868-bib-0015){ref-type="ref"}, [16](#iju13868-bib-0016){ref-type="ref"}, [17](#iju13868-bib-0017){ref-type="ref"}, [18](#iju13868-bib-0018){ref-type="ref"} Overall, similar levels of improvement were observed for all four combination therapies evaluated, regardless of the efficacy parameter investigated.

Although novel data were obtained, the present study does have some limitations. As 1‐year treatment with placebo is ethically problematic, a placebo arm was not included. Additionally, no monotherapy treatment arms were investigated. The trial was open label; a potential source of patient‐ and physician‐associated bias. In addition, 88.1% of the patients were women; a higher proportion than in previous SOLI and MIRA combination studies (66.4--83.9%)[15](#iju13868-bib-0015){ref-type="ref"}, [16](#iju13868-bib-0016){ref-type="ref"}, [17](#iju13868-bib-0017){ref-type="ref"}, [18](#iju13868-bib-0018){ref-type="ref"} and post‐marketing Japanese investigations (50.5--53.2%).[11](#iju13868-bib-0011){ref-type="ref"}, [14](#iju13868-bib-0014){ref-type="ref"} Furthermore, we believe that an antimuscarinic drug should be added to a patient\'s therapeutic regimen if they experience an insufficient response to treatment with MIRA. Alternatively, if a patient does not respond to MIRA, their treatment should be switched from MIRA to an antimuscarinic. However, patients who do not respond to MIRA treatment are infrequently encountered within the clinical setting. Therefore, in the present study, add‐on therapy with antimuscarinics was selected for use during the 52‐week treatment period. However, useful clinical data could be obtained if additional investigations are carried out to compare the efficacy and safety of switching to antimuscarinics with that of MIRA plus antimuscarinic add‐on therapy.

In conclusion, the present study is the first to show the safety and efficacy of long‐term antimuscarinic add‐on therapy in patients with OAB symptoms after initial MIRA treatment. The findings indicate that antimuscarinic add‐on treatment might become a potential clinical option for treating patients with OAB symptoms after the use of first‐line MIRA therapy. Results of additional studies examining the long‐term use of MIRA and antimuscarinics in combination are awaited with interest.
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###### 

**Figure S1.** Change from baseline in mean pulse rate (measured by patients) (a) on awakening and (b) 6 h post‐dose.

###### 

Click here for additional data file.
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**Figure S2.** Change from baseline in mean SBP (measured by patients) (a) on awakening and (b) 6 h post‐dose.
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Click here for additional data file.
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**Figure S3.** Change from baseline in mean DBP (measured by patients) (a) on awakening and (b) 6 h post‐dose.

###### 

Click here for additional data file.
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**Table S1.** Inclusion and exclusion criteria.
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Click here for additional data file.

###### 

**Appendix S1.** MILAI II study group.

###### 

Click here for additional data file.
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